THE ROLE OF BIOLOGICAL RESPONSE MODIFIERS IN THE MANAGEMENT OF PATIENTS WITH COLORECTAL-CANCER

被引：5

作者：

WAGSTAFF, J

机构：

来源：

EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷 / 7-8期

关键词：

COLORECTAL CARCINOMA; BIOLOGICAL RESPONSE MODIFIERS; IMMUNOTHERAPY;

D O I：

10.1016/0959-8049(95)00211-Z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Biological response modifiers are agents which exert their antitumour effects indirectly via modulation of the host's response to the tumour. Immunotherapeutic approaches which fall into this category can be divided into specific and non-specific. An example of the latter is the combination of 5-fluorouracil (5-FU) with levamisole which improves survival of patients with colorectal carcinoma when utilised in an adjuvant setting. Specific immunotherapy using active specific immunisation is attracting much attention. This is in part due to improvements in survival seen in one randomised clinical trial in an adjuvant setting, and also to exciting advances in the fields of tumour immunity and vaccine development. The development of more effective vaccines promises much for patients with early colorectal carcinomas.

引用

页码：1323 / 1325

页数：3

共 29 条

[11]

Rosenberg, Lotze, Yang, Et al., Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients, Ann Surg, 210, pp. 474-485, (1989)

[12]

Rosenberg, Lotze, Yang, Et al., Prospective randomised trial of high dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer, J Natl Cancer Inst, 85, pp. 622-632, (1993)

[13]

Oldham, Blumenschein, Schwartzbert, Birch, Arnold, Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study `Group trial, Molec Biother, 4, pp. 4-9, (1992)

[14]

Hamblin, Inzani, Sadullah, Et al., A phase II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma, Cancer Treat Rev, 16, pp. 163-167, (1989)

[15]

Dillman, Church, Oldham, West, Schwartzenberg, Birch, Inpatient continuous infusion interleukin-2 in 788 patients with cancer, Cancer, 71, pp. 2358-2370, (1993)

[16]

Atzpodien, Korfer, Franks, Poliwoda, Kirchner, Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies, Lancet, 335, pp. 1509-1512, (1990)

[17]

Hoover, Brandhorst, Peters, Et al., Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomised trial, J Clin Oncol, 11, pp. 390-399, (1993)

[18]

Restifo, Kawakami, Marincola, Et al., Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I, J Immunother, 14, pp. 182-190, (1993)

[19]

Chen, Linsley, Hellstrom, Costimulation of T-cells for tumour immunity, Immunology Today, 14, pp. 483-486, (1993)

[20]

Gimmi, Freeman, Gribben, Gray, Nadler, Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation, Proc Natl Acad Sci USA, 90, pp. 6586-6590, (1993)

← 1 2 3 →